CAS: 50-43-1; 2,4,6-Trichlorobenzoic Acid

上下游产品

CAS号4136-95-2 2,4,6-三氯苯酰氯 | CAS号6575-05-9 2,4,6-三氯苯甲腈 | CAS号108-70-3 均三氯苯 | CAS号567-59-9 1,3,5-trichloro... | CAS号124-38-9 二氧化碳 | CAS号88-06-2 2,4,6-三氯苯酚 | CAS号14379-95-4 1,3,5-trichloro... | CAS号23749-65-7 1,3,5-trichloro... | CAS号24473-01-6 3,3-dimethyl-1-... | CAS号4136-95-2 2,4,6-三氯苯酰氯 | CAS号69038-74-0 3-溴苯甲酸叔丁酯 | CAS号217479-60-2 2,4,6-三氯苯甲醇 | CAS号65-85-0 苯甲酸

2,4,6-三氯苯酚置于potassium Carbonate体系中,用 丙酮 作为反应溶剂,化学反应生成 2,4,6-三氯苯甲酸
参考文献:Bisagni,E.; Rivalle,C.,Bulletin De La Societe Chimique De France,1969,P. 3111-3115
标题:Bisagni,E.; Rivalle,C.,Bulletin De La Societe Chimique De France,1969,P. 3111-3115

专利信息

专利号:US-7202256-B2
优先权日:2004-04-14
标题:Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
发明人：GU JIANXIN; RUPPEN MARK E; RAVEENDRANATH PANOLIL; CHEW WARREN; SHAW CHIA-CHENG
权利人:WYETH CORP
摘要:Methods for the synthesis of CCI-779 and proline-CCI-779 are described, including a method involving lipase-catalyzed acetylation of 42-hydroxy of rapamycin with a vinyl ester of 2,2-bis(hydroxymethyl) propionic acid in an organic solvent followed by deprotection. Also provided are products containing proline-CCI-779 and uses thereof.

专利号:US-8258299-B2
优先权日:2009-03-27
标题:Process for preparation of temsirolimus
发明人：LEE KWANG-CHUNG; LEE TING-HUEI; TUNG YEN-SHIH; KAO CHIA-CHEN; LEE TZU-AI
权利人:LEE KWANG-CHUNG; LEE TING-HUEI; TUNG YEN-SHIH; KAO CHIA-CHEN; LEE TZU-AI; CHUNGWA CHEMICAL SYNTHESIS & BIOTECH CO LTD
摘要:The present invention provides two synthetic routes for the preparation of Temsirolimus (compound 1b and analog of Temsirolimus 1a). The first route includes the synthesis of CCI-779 by directly reacting rapamycin (4b) or Prolyl-rapamycin (4a) with substituent-2,2-bis(methoxy) propionic acid anhydride(11) in the presence of an organic base, followed by deprotection to give CCI-779 or Proline CCI-779. The second route includes a process involving a reaction of rapamycin-OH-31-sily ether (4d) or Prolyl-rapamycin-OH-31-sily ether (4c) with substituent-2,2-bis(methoxy) propionic acid anhydride(11) in the presence of an organic base and followed by subsequent hydrolysis step to obtain the desired CCI-779 or Proline CCI-779. n Compound 11, as described in this invention, is stable at room temperature, cost effective and ease of processing.

专利号:US-7153957-B2
优先权日:2003-08-07
标 题:Regioselective synthesis of CCI-779
发明人：CHEW WARREN; SHAW CHIA-CHENG
权利人:WYETH CORP
摘要:A method for regioselective synthesis of CCl-779 based on boronate chemistry is provided. Also provided are novel intermediates useful in this method.

专利号:US-9676698-B2
优先权日:2010-07-20
标 题:Method of producing ingenol-3-angelate
发明人：HOGBERG THOMAS; GRUE-SORENSEN GUNNAR; LIANG XIFU; HORNEMAN ANNE MARIE; PETERSEN ANDERS KLARSKOV
权利人:LEO LABORATORIES LTD
摘要:The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). n n n n n n n n n n Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.

专利号:US-2002058286-A1
优先权日:1999-02-24
标 题 :Synthesis of epothilones, intermediates thereto and analogues thereof
发明人：DANISHEFSKY SAMUEL J; STACHEL SHAWN J; LEE CHUL BOM; CHAPPELL MARK D; CHOU TING-CHAO; WU ZHICAI
摘要:The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.

专利号:US-6867305-B2
优先权日:1996-12-03
标题:Synthesis of epothilones, intermediates thereto and analogues thereof
发明人：DANISHEFSKY SAMUEL J; STACHEL SHAWN J; LEE CHUL BOM; CHAPPELL MARK D; WU ZHICAL
权利人:SLOAN KETTERING INST CANCER; UNIV COLUMBIA
摘要:The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.